芦卡帕利获批用于治疗卵巢癌。
Rucaparib Approved for Ovarian Cancer.
出版信息
Cancer Discov. 2017 Feb;7(2):120-121. doi: 10.1158/2159-8290.CD-NB2016-164. Epub 2017 Jan 5.
Abstract
The FDA approved the PARP inhibitor rucaparib to treat women with advanced ovarian cancer who have already been treated with at least two chemotherapies and have a BRCA1 or BRCA2 gene mutation identified by an approved companion diagnostic test. The agency also gave a nod to the FoundationFocus CDxBRCA test to detect BRCA alterations.
摘要
美国食品药品监督管理局（FDA）批准 PARP 抑制剂芦卡帕利（rucaparib）用于治疗至少接受过两种化疗且经获批伴随诊断检测识别出 BRCA1 或 BRCA2 基因突变的晚期卵巢癌女性。该机构还批准了 FoundationFocus CDxBRCA 检测法，以检测 BRCA 改变。
Zotero 插件